Candesant Biomedical Announces $35M In Series B Financing To Advance Commercialization Of Brella™, The First And Only Fda-Cleared 3-Minute Sweatcontrol Patch™
Candesant Biomedical Announces $35M In Series B Financing To Advance Commercialization Of Brella™, The First And Only Fda-Cleared 3-Minute Sweatcontrol Patch™
06/06/23, 11:03 AM
Location
nashvilleMoney raised
$35 million
Industry
biotechnology
health care
manufacturing
medical device
medical
Round Type
series b
Investors
Correlation Ventures, Astia Fund, Polaris Partners, Kck Med Tech
Candesant Biomedical, Inc. ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive treatments for hyperhidrosis or excessive sweating, today announced the closing of a Series B financing, raising a total of $35 million to advance the commercialization of Brella, the first-and-only FDA-cleared 3-Minute SweatControl Patch. The financing was led by KCK MedTech, a venture capital firm specializing in medical technologies, along with other investors including Polaris Partners, Astia Fund, and Correlation Ventures.
Company Info
Location
3145 geary blvd., suite 711
nashville, arkansas, united states
Additional Info
Candesant Bio is a clinical stage company that is driving research and development of its novel, investigational sweat control patch designed to offer underarm sweat relief with no downtime.
Learn more about our company and technology by visiting Candesant.com